This site is intended for Healthcare Professionals only.

HRA Pharma’s former CEO David Wright joins Ceuta Group

Date:

Share post:

Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a non-executive board director.

With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical company, HRA Pharma and six years as Global Head of Boehringer Ingelheim’s consumer business.

During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to sustainable growth and profitability.

The company said: “David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company’s successful acquisition by Perrigo Company plc.”

David will take an active role on the Ceuta Group Board supporting and building the company’s strategic vision and priorities. He will also help shape the company’s growth plans on an operational level to ensure Ceuta Group continues to meet client’s needs today and into the future.

Commenting on his new role, David said, “Having worked with Ceuta Group while I was at Boehringer and HRA Pharma, I have first hand experience of how it can deliver maximum impact for clients at all stages of growth development. I’m excited to be joining Ceuta Group at this pivotal time and look forward to being a part of its continued success and growth.”

Edwin Bessant, Ceuta Group CEO, said on behalf of the Board of Directors, “David brings extensive global corporate and industry experience and insight to Ceuta Group.

“He has delivered exceptional commercial outcomes in previous roles and we’re absolutely delighted to have him join Ceuta Group as a non-executive board director. His ability to grow successful businesses and teams across the globe will be significant to the future growth of Ceuta Group.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Opioid overdose: Pharmacy professionals to be able to supply naloxone without a prescription

DHSC also publishes a new 10-year strategic plan to expand and improve the drug and alcohol workforce The...

New NHS patient choice scheme offers 5 options, but nursing shortages persist

Royal College of Nursing CE urges caution amidst new NHS patient choice pilot scheme rollout "Patients deserve choice, but...

Prof Ryan Donnelly awarded prestigious RPS Harrison Memorial Medal 2024

RPS HMM winner Professor Donnelly's work has secured £30M+ funding through his pioneering work in developing advanced polymeric...

Pharmacies forced to subsidise NHS medicines: NPA hands £108m invoice to DHSC

The NPA calls for a new deal that reverses “historical funding cuts and gives the sector the respect...